This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Personalis (PSNL), UnitedHealth (UNH) and Biogen (BIIB)

Tipranks - Tipranks - Wed Jul 22, 2:14PM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Personalis (PSNL), UnitedHealth (UNH) and Biogen (BIIB).

Claim 55% Off TipRanks

Personalis (PSNL)

In a report released yesterday, Mark Massaro from BTIG maintained a Buy rating on Personalis, with a price target of $16.25. The company’s shares closed last Tuesday at $13.17.

According to TipRanks.com, Massaro is a 3-star analyst with an average return of 1.6% and a 36.4% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Insight Molecular Diagnostics, Adaptive Biotechnologies, and Tempus AI, Inc. Class A. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Personalis with a $15.58 average price target, a 17.1% upside from current levels. In a report released today, TipRanks – Google also upgraded the stock to Buy with a $15.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

UnitedHealth (UNH)

In a report issued on July 19, Ryan Langston from TD Cowen maintained a Hold rating on UnitedHealth, with a price target of $430.00. The company’s shares closed last Tuesday at $434.32.

According to TipRanks.com, Langston is a 3-star analyst with an average return of 1.3% and a 50.3% success rate. Langston covers the Healthcare sector, focusing on stocks such as Alignment Healthcare, Privia Health Group, and P3 Health Partners. ;'>

Currently, the analyst consensus on UnitedHealth is a Strong Buy with an average price target of $460.00, which is an 8.9% upside from current levels. In a report issued on July 17, Robert W. Baird also upgraded the stock to Hold with a $453.00 price target.

Biogen (BIIB)

In a report released yesterday, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen, with a price target of $215.00. The company’s shares closed last Tuesday at $202.86.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 9.9% and a 51.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, BioMarin Pharmaceutical, and Syndax Pharmaceuticals. ;'>

Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $222.58, representing an 11.6% upside. In a report released today, Guggenheim also assigned a Buy rating to the stock with a $280.00 price target.

Read More on PSNL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).